

Transcriptional Perturbation of Protein Arginine Methyltransferase-5 exhibits MTAP-selective oncosuppression

Sara Busacca¹, Qi Zhang², Annabel Sharkey¹, Alan G. Dawson^{1,6}, David A. Moore^{3,4}, David A. Waller⁵, Apostolos Nakas⁶, Carolyn Jones⁷, Kelvin Cain⁷, Jin-li Luo¹, Adriana Salcedo^{8,9,10}, Iris Salaroglio¹¹, Chiara Riganti¹¹, John Le Quesne^{1,7}, Tom John¹², Paul C. Boutros⁸, Shu-Dong Zhang¹³ and Dean A. Fennell^{1*}







SUPPLEMENTARY TABLES

Supplementary table I. Patient characteristics

	UK cohort (n=79)		AUS cohort (n=100)	
	MTAP CN loss (n=33)	MTAP WT (n=46)	MTAP CN loss (n=63)	MTAP WT (n=37)
Age at diagnosis (median (IQR))	66 (61-74)	63 (55-70)	69 (62-74)	64 (57-74)
Sex (N (%))				
M	29 (88)	38 (83)	53 (84)	28 (76)
F	4 (12)	8 (17)	10 (16)	9 (24)
Survival status (N (%))				
Alive	1 (3)	0 (0)	4 (6)	6 (16)
Dead	32 (97)	46 (100)	59 (94)	31 (84)

Overall survival (months) (median (95% CI))	12.5 (95%CI: 6.8-18.2)	17.6 (95%CI: 6.5-28.7)	8.7 (95%CI: 4.6-12.8)	22.7 (95% CI: 11.4-33.9)
IMIG Stage (N (%))				
1	0 (0)	1 (2)	2 (3)	3 (8)
2	4 (12)	7 (15)	24 (38)	14 (38)
3	24 (73)	28 (61)	30 (48)	17 (46)
4	5 (15)	10 (22)	7 (11)	3 (8)
Histology (N (%))				
Epithelioid	28 (85)	43 (93)	37 (59)	26 (70)
Biphasic	5 (15)	3 (7)	18 (28)	4 (11)
Sarcomatoid	0 (0)	0 (0)	8 (13)	7 (19)
Neoadjuvant chemotherapy administered (N (%))	1 (3)	4 (9)	1 (2)	0 (0)

Supplementary table 2 GSEA analysis

Entrez Gene ID	Gene Symbol	LU EZH2 TARGETS UP	GO ENZYME BINDING	GO PHOSPHATASE INHIBITOR ACTIVITY	GGGCGGR SP1 O6	GO RAB GTPASE BINDING	GGGAGGRR MAZ O6	GO GTPASE BINDING	GARY CD5 TARGETS UP	GO PHOSPHATASE REGULATOR ACTIVITY	WAKABAYASHI ADIPOGENESIS PPARG RXRA BOUND 8D	GSE13306 TREG VS TCONV UP	GSE14308 TH1 VS TH17 DN	GSE14308 TH2 VS TH17 DN	GSE17721 CTRL VS PAM3CSK4 8H BMDC UP	GSE17721 LPS VS POLYIC 4H BMDC DN	GSE21063 3H VS 16H ANTI IGM STIM BCELL DN	GSE22611 MUTANT NOD2 TRANSDUCED VS CTRL HEK293T STIMULATED WITH MDP 6H DN	GSE41176 UNSTIM VS ANTI IGM STIM TAK1 KO BCELL 24H UP	GSE45837 WT VS GF11 KO PDC DN	CCAGGGG MIR331	Entrez Source	Gene Description	
2029	ENSA																						S	endosulfine alpha
114794	ELFN2																						S	extracellular leucine-rich repeat and fibronectin type III domain containing 2
26472	PPP1R14B																						S	protein phosphatase 1, regulatory (inhibitor) subunit 14B
23193	GANAB																						S	glucosidase, alpha; neutral AB
22927	HABP4																						S	hyaluronan binding protein 4
850141	TMEM141																						S	transmembrane protein 141

Supplementary Table 3 Connectivity map analysis

Drug	Replicate	p value	Z score
BRD-K71103788__duloxetine hcl	48	1.85E-10	-6.2659907
BRD-K75641298__METOCLOPRAMIDE HYDROCHLORIDE	29	2.77E-09	-5.8298123
BRD-K36862742__hydro-flumethiazide	141	3.04E-08	-5.4165957
BRD-K99964838__S1014	66	6.16E-08	-5.2888016
BRD-A45889380__QUINACRINE HYDROCHLORIDE	206	8.03E-08	-5.240004
BRD-K91699951__benzonatate	234	1.39E-07	-5.1383754
BRD-K71879491__ATRA	205	2.17E-07	-5.0531872
BRD-A51820102__econazole	36	2.22E-07	-5.0489293
BRD-K37270826__mifepristone	125	2.62E-07	-5.0175175
BRD-K70487031__cis-(Z)- FLUPENTHIXOL	27	3.03E-07	-4.9893544
BRD-K63675182__triflupromazine	179	5.12E-07	-4.8868451
BRD-K89375097__pirenzepine	36	6.96E-07	-4.826062
BRD-K19706299__MRE-269	99	7.54E-07	-4.8102311
BRD-K32164935__TOLAZAMIDE	353	1.17E-06	-4.7219067
BRD-K28936863__ketotifen	85	1.18E-06	-4.7204909
BRD-A23723433__paclitaxel	48	1.22E-06	-4.7138292
BRD-K39621635__artemether	34	1.25E-06	-4.7081455
BRD-K81418486__SAHA__trt_poscon	12	1.36E-06	-4.6910799
BRD-K92093830__doxorubicin	159	1.58E-06	-4.6599437
BRD-A49160188__donepezil	73	1.74E-06	-4.6404777
BRD-K70487031__flupentixol	37	2.14E-06	-4.5971052
BRD-K10916986__S1527	67	2.20E-06	-4.5915996
BRD-K92778217__mefenamic-acid	160	2.39E-06	-4.5741376
BRD-K13514097__S1120	58	3.79E-06	-4.4764562
BRD-K45995181__Auranofin	3	3.84E-06	-4.474083
BRD-K66175015__S1011	59	4.68E-06	-4.4316279
BRD-K53737926__amitryptiline	137	4.95E-06	-4.4194573
BRD-K52075040__cerulenin	210	5.16E-06	-4.4103748
BRD-K20075662__betazole	143	5.27E-06	-4.4059091
BRD-K33106058__cytarabine	48	5.52E-06	-4.395691
BRD-K91290917__Amodiaquin dihydrochloride dihydrate	57	5.65E-06	-4.3905396
BRD-K81418486__vorinostat	1303	6.50E-06	-4.360225
BRD-K93754473__tamoxifen	843	6.59E-06	-4.3571007
BRD-K25433859__maprotiline	37	9.22E-06	-4.2829289
BRD-K39339537__epirizole	217	1.16E-05	-4.2316941
BRD-A45889380__Quinacrine dihydrochloride dihydrate	10	1.58E-05	-4.1619013
BRD-K81528515__HY-10159	66	1.60E-05	-4.1585908

BRD-K17016787__estriol	355	1.78E-05	-4.1344654
BRD-K21680192__mitoxantrone	334	1.91E-05	-4.1181513
BRD-K41260949__Sodium Valproate	45	2.33E-05	-4.0721889
BRD-K39987650__BISACODYL	93	2.54E-05	-4.0520213
BRD-K89997465__CHLORPROMAZINE	86	2.68E-05	-4.0390003
BRD-K81418486__VORINOSTAT__trt_poscon	2575	3.07E-05	-4.0072094
BRD-K63750851__mycophenolic-acid	31	3.78E-05	-3.9582377
BRD-K47869605__podofilox	72	3.85E-05	-3.9538222
BRD-K61250553__Loperamide.HCl	23	3.91E-05	-3.9501318
BRD-K20168442__vecuronium	49	4.36E-05	-3.9234926
BRD-K61250553__imodium	45	4.38E-05	-3.9224636
BRD-A29734509__norpace	44	5.30E-05	-3.8764725
BRD-K28143534__Cyproheptadine hydrochloride	10	1.07E-04	-3.7019795
BRD-K86434416__deprenalin	88	1.31E-04	-3.6498136

SUPPLEMENTARY METHODS

Clonogenic assays

5000 cells per well were seeded in 12 well plates and left untreated or treated with EPZ015666 (1 μ M, 5 μ M, 10 μ M). The PRMT5 inhibitor EPZ015666 was obtained from Selleckchem (Ely, UK).

Five days after treatment, cells were fixed on ice in methanol for 20 minutes. Cells were then stained with crystal violet (Sigma, Gillingham, UK) for 10 minutes. Colonies were dissolved in 30% acetic acid to allow quantification. Each treatment condition was measured in triplicate.

siRNA transfections

The non-silencing control (NT) and siRIOK, were obtained from and Qiagen (Manchester, UK). siRNA transfections (20 nM) were performed using the RNAiMAX transfection reagent (Invitrogen, Paisley, UK) according to manufacturer's instructions.

Flow Cytometry

Samples were analysed on a BD FACS Calibur flow cytometer machine, using Cell Quest Pro software (Becton Dickinson, Oxford, UK). Cells were fixed after 16, 32, 72 and 120 hours of treatment with quinacrine, EPZ015666 or after silencing of PRMT5 and stained with propidium iodide (Sigma).

Gene expression

NCI-H2591 and NCI-H2052 cells were transfected with non-silencing control (NT), siPRMT5 Qiagen and siPRMT5 Dharmacon. RNA was extracted 120h after transfection with the RNeasy Mini Kit (Qiagen, Manchester, UK) and 100 ng of RNA were hybridised on the SurePrint G3 Human Gene Expression v3 8x60k array (Agilent, Cheadle, UK).

Gene expression dataset was analysed using Limma in R/Bioconductor software package. Comparisons were performed siQ vs siNT, siD vs siNT. Gene lists were then filtered by fold change ≥ 2 , unadjusted p value ≤ 0.05 . Webgestalt (<http://www.webgestalt.org/>) was used to perform Gene Ontology, KEGG pathway, Pathway Common, Wiki Pathway. GSEA Molecular Signatures Database (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>) was used to investigate 85 upregulated gene set.

SUPPLEMENTARY FIGURE LEGENDS


Supplementary Figure 1. A) Cells were transfected with siNT or siRIOK1 20 nM. Cell proliferation was measured by clonogenic assay. Data were normalized to siNT controls (NCI-H2591: $p = \text{n.s.}$; NCI-H2052: $p = 0.0001$; NCI-H2452: $p = \text{n.s.}$; MPP89: $p = \text{n.s.}$). The levels of PRMT5 expression and H4 arginine 3 symmetrical di-methylation (H4R3me2S) were measured by western blot 72 hours after transfection. These gels have been cropped and the full length gels are presented in Supplementary Figure 3 M-O. **B)** Flow cytometry plot showing cells transfected with siNT or siPRMT5 for 120 hours. **C)** Cells were left untreated or treated with EPZ015666 1 μM , 5 μM and 10 μM . Cell proliferation was measured by clonogenic assay 5-7 days after treatment. Data were normalized to untreated controls (NCI-H2591: 1 μM $p = 0.0176$; 5 μM $p = 0.0001$; 10 μM $p = 0.0001$; NCI-H2052: 1 μM $p = \text{n.s.}$; 5 μM $p = \text{n.s.}$ 10 μM $p = 0.0033$; MPP89: 1 μM $p = \text{n.s.}$; 5 μM $p = \text{n.s.}$ 10 μM $p = \text{n.s.}$). **D)** Flow cytometry plot showing cells left untreated or treated with EPZ015666 5 μM and 10 μM for 72 hours.

Supplementary Figure 2. Flow cytometry plot showing cells left untreated or treated with quinacrine 1 μM for 120 hours. **B)** Flow cytometry plot showing cells transfected with siNT, sic-JUN 20 nM, for 120 hours.


Supplementary Figure 3. Uncropped images of full length gels used throughout the manuscript. **A-C:** Full length gels of cropped gels in Figure 1C (A: NCI-H2591; B: NCI-H2052; C: MPP89); **D-F:** Full length gels of cropped gels in Figure 1D (D: NCI-H2591; E: NCI-2052; F: MPP89); **G-I:** Full length gels of cropped gels in Figure 3C (G: NCI-H2591; H: NCI-H2052; I: MPP89); **J-K:** Full length gels of cropped gels in Figure 4B (J: NCI-H2591; K: NCI-H2052); **L:** Full length gel of cropped gel in Figure 4E; **M-O:**

Full length gels of cropped gels in Supplementary Figure 1A (M: NCI-H2591; N: NCI-H2052; O: MPP89).



Supplementary Figure 1.




Supplementary Figure 2.




Supplementary Figure 3.







E




F




G




H




I




J




K




L



M



N



O